Home
About
FAQ
History (14)
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.
Thiosulfates
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer.
Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity.
Noncytotoxic differentiation treatment of renal cell cancer.
See All 14 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Noncytotoxic differentiation treatment of renal cell cancer.
Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res. 2011 Feb 15; 71(4):1431-41.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Apoptosis
Azacitidine
Carcinoma, Renal Cell
Cell Differentiation
Cell Line, Tumor
Cell Survival
Cytotoxins
DNA Damage
Humans
Kidney Neoplasms
Mice
Mice, Nude
Xenograft Model Antitumor Assays
authors with profiles
Pierre L. Triozzi MD